{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:31:06Z","timestamp":1791808266319,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bbcan.2021.188578","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:04:46Z","timestamp":1623153886000},"page":"188578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["The interaction of SET and protein phosphatase 2A as target for cancer therapy"],"prefix":"10.1016","volume":"1876","author":[{"given":"E.C.","family":"Dacol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Lepique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bbcan.2021.188578_bb0005","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/cam4.1526","article-title":"A comprehensive and perspective view of oncoprotein SET in cancer","volume":"7","author":"Bayarkhangai","year":"2018","journal-title":"Cancer Med."},{"issue":"16","key":"10.1016\/j.bbcan.2021.188578_bb0010","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1016\/j.febslet.2006.06.021","article-title":"Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine","volume":"580","author":"Chohan","year":"2006","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.bbcan.2021.188578_bb0015","first-page":"3346","article-title":"Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3\u2019half to different genes: characterization of the set gene","volume":"12","author":"Von Lindern","year":"1992","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.bbcan.2021.188578_bb0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/excr.1997.3930","article-title":"Cellular localization and expression of template-activating factor I in different cell types","volume":"240","author":"Nagata","year":"1998","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjh.15677","article-title":"SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia","volume":"184","author":"Brander","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"40","key":"10.1016\/j.bbcan.2021.188578_bb0030","doi-asserted-by":"crossref","first-page":"67966","DOI":"10.18632\/oncotarget.19067","article-title":"SET contributes to the epithelial-mesenchymal transition of pancreatic cancer","volume":"8","author":"Mody","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bbcan.2021.188578_bb0035","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.neurobiolaging.2012.12.025","article-title":"Ser9 phosphorylation causes cytoplasmic detention of I2PP2A\/SET in Alzheimer disease","volume":"34","author":"Yu","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.bbcan.2021.188578_bb0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0092-8674(03)00150-8","article-title":"Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor","volume":"112","author":"Fan","year":"2003","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2021.188578_bb0045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.emboj.7601518","article-title":"Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET","volume":"26","author":"ten Klooster","year":"2007","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.bbcan.2021.188578_bb0050","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.0603762104","article-title":"Relationship between the structure of SET\/TAF-I\u03b2\/INHAT and its histone chaperone activity","volume":"104","author":"Muto","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2021.188578_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/MCB.25.2.797-807.2005","article-title":"The histone chaperone TAF-I\/SET\/INHAT is required for transcription in vitro of chromatin templates","volume":"25","author":"Gamble","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13072-015-0022-8","article-title":"Eviction of linker histone H1 by NAP-family histone chaperones enhances activated transcription","volume":"8","author":"Zhang","year":"2015","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0092-8674(01)00196-9","article-title":"Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein","volume":"104","author":"Seo","year":"2001","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.bbcan.2021.188578_bb0070","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1128\/MCB.20.23.8933-8943.2000","article-title":"Functional interaction between nucleosome assembly proteins and p300\/CREB-binding protein family coactivators","volume":"20","author":"Shikama","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"14","key":"10.1016\/j.bbcan.2021.188578_bb0075","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00018-013-1525-8","article-title":"Inhibition of Ku70 acetylation by INHAT subunit SET\/TAF-I\u03b2 regulates Ku70-mediated DNA damage response","volume":"71","author":"Kim","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3324\/haematol.2011.050542","article-title":"Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia","volume":"97","author":"Crist\u00f3bal","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bbcan.2021.188578_bb0085","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.oraloncology.2012.05.014","article-title":"SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification","volume":"48","author":"Leopoldino","year":"2012","journal-title":"Oral Oncol."},{"issue":"25","key":"10.1016\/j.bbcan.2021.188578_bb0090","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1073\/pnas.1317630111","article-title":"Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer","volume":"111","author":"Janghorban","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep15182","article-title":"Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET-PP2A signaling axis","volume":"5","author":"Hu","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/jcm8030346","article-title":"Deregulation of SET is associated with tumor progression and predicts adverse outcome in patients with early-stage colorectal cancer","volume":"8","author":"Crist\u00f3bal","year":"2019","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.bbcan.2021.188578_bb0105","doi-asserted-by":"crossref","first-page":"14913","DOI":"10.18632\/oncotarget.3818","article-title":"Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"37","key":"10.1016\/j.bbcan.2021.188578_bb0110","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1038\/onc.2016.21","article-title":"Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential","volume":"35","author":"Hung","year":"2016","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.bbcan.2021.188578_bb0115","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1681\/ASN.V9101873","article-title":"Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms\u2019 tumor","volume":"9","author":"Carlson","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"issue":"33","key":"10.1016\/j.bbcan.2021.188578_bb0120","doi-asserted-by":"crossref","first-page":"53989","DOI":"10.18632\/oncotarget.9840","article-title":"MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia","volume":"8","author":"Pippa","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0270-0","article-title":"A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia","volume":"10","author":"Arriazu","year":"2020","journal-title":"Blood Cancer J."},{"issue":"7623","key":"10.1016\/j.bbcan.2021.188578_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature19759","article-title":"Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode","volume":"538","author":"Wang","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12253-020-00797-0","article-title":"The function of NM23-H1\/NME1 and its homologs in major processes linked to metastasis","volume":"26","author":"M\u00e1ty\u00e1si","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Janssens","year":"2001","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.bbcan.2021.188578_bb0145","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1021\/bi00006a020","article-title":"Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney","volume":"34","author":"Li","year":"1995","journal-title":"Biochemistry"},{"issue":"19","key":"10.1016\/j.bbcan.2021.188578_bb0150","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","article-title":"The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A","volume":"271","author":"Li","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.bbcan.2021.188578_bb0155","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.febslet.2011.07.020","article-title":"Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A\/SET","volume":"585","author":"Arnaud","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbcan.2021.188578_bb0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biocel.2018.01.005","article-title":"Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer","volume":"96","author":"Kauko","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2021.188578_bb0165","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0006-2952(00)00424-X","article-title":"Type 2A protein phosphatase, the complex regulator of numerous signaling pathways","volume":"60","author":"Zolnierowicz","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nmeth731","article-title":"Kinomics: methods for deciphering the kinome","volume":"2","author":"Johnson","year":"2005","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.bbcan.2021.188578_bb0175","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.celrep.2015.07.016","article-title":"A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation","volume":"12","author":"Yang","year":"2015","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0185","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1074\/jbc.M709585200","article-title":"Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55\u03b1 regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt","volume":"283","author":"Kuo","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0190","first-page":"19","article-title":"Physiological regulation of Akt activity and stability","volume":"2","author":"Liao","year":"2010","journal-title":"Am. J. Transl. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0195","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3892\/or.2017.5788","article-title":"Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer","volume":"38","author":"Yuan","year":"2017","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/gcc.22312","article-title":"Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies","volume":"55","author":"Routila","year":"2016","journal-title":"Genes Chromosom. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0205","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbamcr.2019.01.005","article-title":"SET protein accumulation prevents cell death in head and neck squamous cell carcinoma through regulation of redox state and autophagy","volume":"1866","author":"Ouchida","year":"2019","journal-title":"Biochim. Biophy. Acta Mol. Cell Res."},{"issue":"16","key":"10.1016\/j.bbcan.2021.188578_bb0210","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1242\/jcs.03473","article-title":"GSK-3\u03b2 acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis","volume":"120","author":"Lin","year":"2007","journal-title":"J. Cell Sci."},{"issue":"52","key":"10.1016\/j.bbcan.2021.188578_bb0215","doi-asserted-by":"crossref","first-page":"42644","DOI":"10.1074\/jbc.M502464200","article-title":"Positive regulation of Raf1-MEK1\/2-ERK1\/2 signaling by protein serine\/threonine phosphatase 2A holoenzymes","volume":"280","author":"Adams","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0220","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1515\/bmc-2013-0003","article-title":"Raf kinases in signal transduction and interaction with translation machinery","volume":"4","author":"Migliaccio","year":"2013","journal-title":"Biomol. Concepts"},{"issue":"46","key":"10.1016\/j.bbcan.2021.188578_bb0225","doi-asserted-by":"crossref","first-page":"31429","DOI":"10.1074\/jbc.M802855200","article-title":"Characterization of Ser338 phosphorylation for Raf-1 activation","volume":"283","author":"Zang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2021.188578_bb0230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2018.12.032","article-title":"Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression","volume":"40","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"issue":"48","key":"10.1016\/j.bbcan.2021.188578_bb0235","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1038\/sj.onc.1207077","article-title":"Type-2A protein phosphatase activity is required to maintain death receptor responsiveness","volume":"22","author":"H\u00e4rm\u00e4l\u00e4-Brask\u00e9n","year":"2003","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.bbcan.2021.188578_bb0240","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/pros.23898","article-title":"Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling","volume":"79","author":"Shishodia","year":"2019","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/0008-5472.CAN-16-1267-T","article-title":"PROTOCADHERIN 7 acts through SET and PP2A to potentiate MAPK signaling by EGFR and KRAS during lung tumorigenesis","volume":"77","author":"Zhou","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188578_bb0250","series-title":"c-Myc and Cancer Metabolism","author":"Miller","year":"2012"},{"issue":"9","key":"10.1016\/j.bbcan.2021.188578_bb0255","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4161\/cc.3.9.1145","article-title":"The life cycle of C-myc: from synthesis to degradation","volume":"3","author":"Sears","year":"2004","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.bbcan.2021.188578_bb0260","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.118117","article-title":"CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia","volume":"100","author":"Barrag\u00e1n","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bbcan.2021.188578_bb0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.bbcan.2021.188578_bb0270","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","article-title":"Targeting SET\/I 2 PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy","volume":"30","author":"Switzer","year":"2011","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cdd.2017.174","article-title":"Mechanisms of transcriptional regulation by p53","volume":"25","author":"Sullivan","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0280","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-18-0485","article-title":"p53 function is compromised by inhibitor 2 of phosphatase 2A in sonic hedgehog medulloblastoma","volume":"17","author":"Wei","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrd2781","article-title":"Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls","volume":"8","author":"Baud","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"26","key":"10.1016\/j.bbcan.2021.188578_bb0290","doi-asserted-by":"crossref","first-page":"40285","DOI":"10.18632\/oncotarget.9603","article-title":"Isoliensinine induces dephosphorylation of NF-\u03baB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A\/I2PP2A interaction","volume":"7","author":"Shu","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0295","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1541-7786.MCR-17-0393","article-title":"Stemness is enhanced in gastric cancer by a SET\/PP2A\/E2F1 axis","volume":"16","author":"Enjoji","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188578_bb0300","series-title":"Critical ReviewsTM in Oncogenesis","article-title":"On the origin of cancer metastasis","volume":"18","author":"Seyfried","year":"2013"},{"issue":"12","key":"10.1016\/j.bbcan.2021.188578_bb0305","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.cellsig.2014.08.010","article-title":"SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell","volume":"26","author":"Liu","year":"2014","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.bbcan.2021.188578_bb0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1078-0432.CCR-14-0724","article-title":"Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer","volume":"21","author":"Crist\u00f3bal","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2021.188578_bb0315","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1541-7786.MCR-13-0542","article-title":"Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer","volume":"12","author":"Farrell","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2021.188578_bb0320","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/bph.13759","article-title":"Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion","volume":"174","author":"Ward","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-32","article-title":"Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models","volume":"13","author":"Sobral","year":"2014","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0330","doi-asserted-by":"crossref","first-page":"638","DOI":"10.18632\/oncotarget.6313","article-title":"SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A","volume":"7","author":"Hung","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0335","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/1061186X.2016.1245307","article-title":"SET protein overexpression contributes to paclitaxel resistance in MCF-7\/S cells through PI3K\/Akt pathway","volume":"25","author":"Zhang","year":"2017","journal-title":"J. Drug Target."},{"issue":"9","key":"10.1016\/j.bbcan.2021.188578_bb0340","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4161\/cbt.20562","article-title":"Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling","volume":"13","author":"Bareford","year":"2012","journal-title":"Cancer Biol. Therapy"},{"issue":"9","key":"10.1016\/j.bbcan.2021.188578_bb0345","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/jcm7090245","article-title":"SET overexpression is associated with worse recurrence-free survival in patients with primary breast cancer receiving adjuvant tamoxifen treatment","volume":"7","author":"Huang","year":"2018","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2021.188578_bb0350","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.0611532104","article-title":"Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56\u03b4 subunit","volume":"104","author":"Ahn","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"47","key":"10.1016\/j.bbcan.2021.188578_bb0355","doi-asserted-by":"crossref","first-page":"32671","DOI":"10.1074\/jbc.M114.604983","article-title":"67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance","volume":"289","author":"Tsukamoto","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0360","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc3398","article-title":"Ceramide-orchestrated signalling in cancer cells","volume":"13","author":"Morad","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.bbcan.2021.188578_bb0365","doi-asserted-by":"crossref","first-page":"15523","DOI":"10.1016\/S0021-9258(18)82288-8","article-title":"Ceramide activates heterotrimeric protein phosphatase 2A","volume":"268","author":"Dobrowsky","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0370","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1096\/fj.08-120550","article-title":"Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling","volume":"23","author":"Mukhopadhyay","year":"2009","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.bbcan.2021.188578_bb0375","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0976-500X.77118","article-title":"Fingolimod (FTY720): first approved oral therapy for multiple sclerosis","volume":"2","author":"Sharma","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0385","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/emmm.201201283","article-title":"Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis","volume":"5","author":"Saddoughi","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2021.188578_bb0390","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome\u2013positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0395","first-page":"1","article-title":"Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic","volume":"19","author":"Brown","year":"2019","journal-title":"BMC Neurol."},{"issue":"10","key":"10.1016\/j.bbcan.2021.188578_bb0400","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bbcan.2021.188578_bb0405","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"Oaks","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2021.188578_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.10.007","article-title":"A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity","volume":"468","author":"Vicente","year":"2020","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0415","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.4049\/jimmunol.1002847","article-title":"Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A","volume":"186","author":"Christensen","year":"2011","journal-title":"J. Immunol."},{"issue":"51","key":"10.1016\/j.bbcan.2021.188578_bb0420","doi-asserted-by":"crossref","first-page":"84214","DOI":"10.18632\/oncotarget.12394","article-title":"Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia","volume":"7","author":"Richard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2021.188578_bb0425","series-title":"A Novel SET Antagonist (OP449) is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors","author":"Agarwal","year":"2011"},{"key":"10.1016\/j.bbcan.2021.188578_bb0430","doi-asserted-by":"crossref","first-page":"173268","DOI":"10.1016\/j.ejphar.2020.173268","article-title":"Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma","volume":"882","author":"Goto","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2021.188578_bb0435","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10989-017-9633-1","article-title":"Identification of PP2A\/set binding sites and design of interacting peptides with potential clinical applications","volume":"24","author":"Tian","year":"2018","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.bbcan.2021.188578_bb0440","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.11.012","article-title":"EGFR-independent Elk1\/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells","volume":"72","author":"Liu","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2021.188578_bb0445","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.118.249102","article-title":"Antagonizing SET augments the effects of radiation therapy in hepatocellular carcinoma through reactivation of PP2A-mediated Akt Downregulation","volume":"366","author":"Huang","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"14","key":"10.1016\/j.bbcan.2021.188578_bb0450","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.18632\/oncotarget.3665","article-title":"Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2021.188578_bb0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ptr.5732","article-title":"A comprehensive review on chemical profiling of Nelumbo nucifera: potential for drug development","volume":"31","author":"Sharma","year":"2017","journal-title":"Phytother. Res."},{"issue":"40","key":"10.1016\/j.bbcan.2021.188578_bb0460","doi-asserted-by":"crossref","first-page":"8793","DOI":"10.1021\/acs.jafc.5b02993","article-title":"Isoliensinine, a bioactive alkaloid derived from embryos of Nelumbo nucifera, induces hepatocellular carcinoma cell apoptosis through suppression of NF-\u03baB signaling","volume":"63","author":"Shu","year":"2015","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bbcan.2021.188578_bb0465","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3389\/fphar.2021.630385","article-title":"Isoliensinine: a natural compound with \u201cdrug-like\u201d potential","volume":"12","author":"Cheng","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X21000755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X21000755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:46:56Z","timestamp":1759639616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X21000755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0304419X21000755"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2021.188578","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interaction of SET and protein phosphatase 2A as target for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2021.188578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188578"}}